FDBK vs. RENX, COG, INHC, IQAI, TRLS, DVRG, SENS, EMIS, CRW, and INS
Should you be buying Feedback stock or one of its competitors? The main competitors of Feedback include Renalytix (RENX), Cambridge Cognition (COG), Induction Healthcare Group (INHC), IQ-AI (IQAI), Trellus Health (TRLS), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry.
Feedback vs. Its Competitors
Renalytix (LON:RENX) and Feedback (LON:FDBK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.
25.6% of Renalytix shares are owned by institutional investors. Comparatively, 92.3% of Feedback shares are owned by institutional investors. 6.7% of Renalytix shares are owned by insiders. Comparatively, 8.0% of Feedback shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Renalytix has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Feedback has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
Feedback has a net margin of -279.16% compared to Renalytix's net margin of -1,191.75%. Renalytix's return on equity of 293.20% beat Feedback's return on equity.
In the previous week, Feedback had 2 more articles in the media than Renalytix. MarketBeat recorded 2 mentions for Feedback and 0 mentions for Renalytix. Feedback's average media sentiment score of 0.37 beat Renalytix's score of 0.00 indicating that Feedback is being referred to more favorably in the news media.
Feedback has lower revenue, but higher earnings than Renalytix. Feedback is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
Summary
Feedback beats Renalytix on 7 of the 13 factors compared between the two stocks.
Get Feedback News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDBK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FDBK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Feedback Competitors List
Related Companies and Tools
This page (LON:FDBK) was last updated on 9/13/2025 by MarketBeat.com Staff
Free FDBK Stock Alerts